➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Medtronic
Moodys
Express Scripts

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 7,015,018

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,015,018
Title:Amplification method for detection of target nucleic acids involving-fluorescence energy transfer
Abstract: A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising subjecting said sample to an amplification reaction using a set of nucleotides, at least one of which is labelled with a first label, and a reagent comprising an amplification primer which can hybridise to said target sequence when in single stranded form and which is connected at its 5\' end to a probe which carries a second label by way of a chemical linking group, said labelled probe being of a sequence which is similar to that of the said target sequence, such that it can hybridise to a complementary region in an amplification product, and wherein one of the first or the second label comprises a donor label and the other comprises an acceptor label, the donor label comprising a fluorescent molecule which is able to donate fluorescent energy to the acceptor label; and monitoring fluorescence of said sample. The method can be used to quantitate the amount of target nucleic acid in the sample as well as to determine sequence characteristics. Kits for effecting the method are also claimed.
Inventor(s): Lee; Martin Alan (Salisbury, GB), Leslie; Dario Lyall (Salisbury, GB)
Assignee: The Secretary of State for Defence in Her Brittanic Majesty\'s Government of the United Kingdom of Great Britain and Northern Ireland. (Salisbury, GB) N/A (N/A)
Application Number:10/048,752
Patent Claims:see list of patent claims

Details for Patent 7,015,018

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Secretary of State for Defence in Her Brittanic Majesty\'s Government of the United Kingdom of Great Britain and Northern Ireland. (Salisbury, GB) N/A (N/A) 2019-08-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Secretary of State for Defence in Her Brittanic Majesty\'s Government of the United Kingdom of Great Britain and Northern Ireland. (Salisbury, GB) N/A (N/A) 2019-08-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Secretary of State for Defence in Her Brittanic Majesty\'s Government of the United Kingdom of Great Britain and Northern Ireland. (Salisbury, GB) N/A (N/A) 2019-08-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
McKesson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.